Appendix G. Summary Results From Unadjusted NRCS

Table G-1. Summary results from unadjusted NRCS

| Author year PMID | Total N (patients) | Lesion type (location) | Treatment | Treatment notes | Outcome (lack of clearance/ recurrence) | n patients (in arm)/N patients (in arm) (% patients) | n lesions (arm)/N lesions (in arm) (% lesions) | Odds Ratio (95% CI) | Adverse events reported (y/n) | Aditional outcomes reported |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Rank 1973 4700671 | 1942 | BCC | A. Surgical Excision without interoperative evaluation | unclear whether the n here is lesions or patients | Recurrence | 3/566 (0.5) |  | *A vs. D1: 0.14 (0.04, 0.47)* | n |  |
| Rank 1973 4700671 | 1942 | BCC | D1. External beam radiation | unclear whether the n here is lesions or patients | Recurrence | 31/857 (3.6) |  |  | n |  |
| Rank 1973 4700671 | 1942 | SCC | A. Surgical Excision without interoperative evaluation | unclear whether the n here is lesions or patients | Recurrence | 4/288 (1.4) |  | A vs. D1: 0.45 (0.13, 1.56) | n |  |
| Rank 1973 4700671 | 1942 | SCC | D1. External beam radiation | unclear whether the n here is lesions or patients | Recurrence | 7/231 (3) |  |  | n |  |
| Chernosky 1978 663726 | 1898 | BCC + SCC | A. Surgical Excision without interoperative evaluation |  | Recurrence |  | 6/494 (1.21) | A vs. D1: 0.47 (0.17, 1.31) | n |  |
| Chernosky 1978 663726 | 1898 | BCC + SCC | D1. External beam radiation |  | Recurrence |  | 10/395 (2.53) | D1 vs. C2: 1.53 (0.77, 3.07) | n |  |
| Chernosky 1978 663726 | 1898 | BCC + SCC | C2. Diathermy/electrodessication |  | Recurrence |  | 46/2763 (1.66) | A vs. C2: 0.73 (0.31, 1.71) | n |  |
| Mazeron 1988 3146781 | 1326 | BCC + SCC (nose) | D2. Brachytherapy/Pleisiotherapy | interstitial implantation  | Recurrence |  | 19/578 (3.3) | D2 vs. D1 (ortho): 0.68 (0.38, 1.21) | y | cosmetic outcomes |
| Mazeron 1988 3146781 | 1326 | BCC + SCC (nose) | D1. External beam radiation | orthovoltage | Recurrence |  | 31/648 (4.7) | *D1 (ortho) vs. D1 (mega): 0.21 (0.12, 0.4)* | y | cosmetic outcomes |
| Mazeron 1988 3146781 | 1326 | BCC + SCC (nose) | D1. External beam radiation | megavoltage | Recurrence |  | 19/100 (19) | *D2 vs. D1 (mega): 0.14 (0.07, 0.29)* | y | cosmetic outcomes |
| Knox 1967 6020491 | 1417 | BCC | D1. External beam radiation | xray | Lack of cure |  | 7/144 (4.8) | A vs. D1: 0.66 (0.25, 1.73) | n |  |
| Knox 1967 6020491 | 1417 | BCC | A. Surgical Excision without interoperative evaluation |  | Lack of cure |  | 11/339 (3.2) | A vs. C2: 1.84 (0.85, 3.96) | n |  |
| Knox 1967 6020491 | 1417 | BCC | C2. Diathermy/electrodessication |  | Lack of cure |  | 17/948 (1.8) | *D1 vs. C2: 2.8 (1.14, 6.87)* | n |  |
| Knox 1967 6020491 | 1417 | SCC | D1. External beam radiation | xray | Lack of cure |  | 8/101 (7.9) | A vs. D1: 0.52 (0.19, 1.38) | n |  |
| Knox 1967 6020491 | 1417 | SCC | A. Surgical Excision without interoperative evaluation |  | Lack of cure |  | 9/211 (4.3) | *A vs. C2: 3.42 (1.26, 9.32)* | n |  |
| Knox 1967 6020491 | 1417 | SCC | C2. Diathermy/electrodessication |  | Lack of cure |  | 7/545 (1.3) | *D1 vs. C2: 6.61 (2.34, 18.67)* | n |  |
| Tourli 2016 26870972 | 1380 | BCC (head and neck region) | A. Surgical Excision without interoperative evaluation | wide excision | Recurrence |  | 5/380 (1.4) | *A vs B: 5.65 (1.34, 23.75)* | n |  |
| Tourli 2016 26870972 | 1380 | BCC (head and neck region) | B. Surgical Excision with interoperative evaluation | delayed Mohs | Recurrence |  | 3/1274 (0.23) |  | n |  |
| Ashby 1989 2702595 | 1154 | BCC + SCC | A. Surgical Excision without interoperative evaluation |  | Lack of cure | 18/614 (2.9) |  | *A vs. D1: 0.46 (0.25, 0.83)* | n |  |
| Ashby 1989 2702595 | 1154 | BCC + SCC | D1. External beam radiation |  | Lack of cure | 30/482 (6.2) |  | D1 vs. C1: 0.73 (0.09, 5.85) | n |  |
| Ashby 1989 2702595 | 1154 | BCC + SCC | C1. Cryotherapy |  | Lack of cure | 1/12 (8.3) |  | A vs. C1: 0.33 (0.04, 2.71) | n |  |
| Futoryan 1995 7773598 | 1047 | BCC + SCC | B. Surgical Excision with interoperative evaluation |  | infection |  | 13/530 (2.5) | A vs. B: 0.86 (0.38, 1.95) | y |  |
| Futoryan 1995 7773598 | 1047 | BCC + SCC | A. Surgical Excision without interoperative evaluation |  | infection |  | 11/517 (2.1) |  | y |  |
| Honeycutt 1973 4750203 | 484 | SCC | C2. Diathermy/electrodessication |  | Recurrence |  | 3/281 (1.1) |  | n |  |
| Honeycutt 1973 4750203 | 484 | SCC | D1. External beam radiation |  | Recurrence |  | 0/18 (0) |  | n |  |
| Honeycutt 1973 4750203 | 484 | SCC lip | C2. Diathermy/electrodessication |  | Recurrence |  | 3/29 (10.3) | A vs. C2: 1.24 (0.18, 8.31) | n |  |
| Honeycutt 1973 4750203 | 484 | SCC lip | A. Surgical Excision without interoperative evaluation |  | Recurrence |  | 2/16 (12.5) |  | n |  |
| Jebodhsingh 2012 22560426 | 385 | BCC (periocular) | A. Surgical Excision without interoperative evaluation |  | Recurrence | 51/346 (15) |  | A vs. B: 2.31 (0.69, 7.73) | n |  |
| Jebodhsingh 2012 22560426 | 385 | BCC (periocular) | B. Surgical Excision with interoperative evaluation | Mohs | Recurrence | 3/43 (8) |  |  | n |  |
| Van Hezewijk 2010 | 333 | BCC + SCC | D1. External beam radiation | 54 gy | Recurrence |  | 5/159 (3.1) | D1 (high dose) vs. D1 (low dose): 0.86 (0.29, 2.56) | n | cosmetic outcomes |
| Van Hezewijk 2010 | 333 | BCC + SCC | D1. External beam radiation | 44 gy | Recurrence |  | 10/275 (3.6) |  | n | cosmetic outcomes |
| Hansen 2008 18363722 | 298 | Bowen's | A. Surgical Excision without interoperative evaluation | elliptical or shave excision | Recurrence |  | 8/188 (4.3) |  | n |  |
| Hansen 2008 18363722 | 298 | Bowen's | C1. Cryotherapy |  | Recurrence |  | 2/24 (8.3) |  | n |  |
| Hansen 2008 18363722 | 298 | Bowen's | C3. Curettage + diathermy | Curettage and fulgaration | Recurrence |  | 2/46 (4.3) |  | n |  |
| Hansen 2008 18363722 | 298 | Bowen's | F1. Topical or intralesional 5-FU...Define:  | topical | Recurrence |  | 1/24 (4.2) |  | n |  |
| Hansen 2008 18363722 | 298 | Bowen's | B. Surgical Excision with interoperative evaluation | Mohs | Recurrence |  | 2/83 (2.4) |  | n |  |
| Hansen 2008 18363722 | 298 | Bowen's | C2. Diathermy/electrodessication |  | Recurrence |  | 0/16 (0) |  | n |  |
| Hansen 2008 18363722 | 298 | Bowen's | F2. Topical or intralesional Imiquimod...Define:  | topical | Recurrence |  | 0/7 (0) |  | n |  |
| Pereira 2013 23486132 | 289 | NMSC | A. Surgical Excision without interoperative evaluation |  | Recurrence | 29/289 (10) |  | *A vs. B: 3.61 (1.47, 8.86)* | n |  |
| Pereira 2013 23486132 | 289 | NMSC | B. Surgical Excision with interoperative evaluation | Mohs | Recurrence | 6/200 (3) |  |  | n |  |
| Nevrkla 1974 4425623 | 200 | BCC | A. Surgical Excision without interoperative evaluation |  | Recurrence | 1/35 (2.9) |  | A vs. D1: 0.44 (0.05, 3.68) | y |  |
| Nevrkla 1974 4425623 | 200 | BCC | D1. External beam radiation | low-voltage x-rays | Recurrence | 8/129 (6.2) |  | D1 vs D2: 0.73 (0.18, 2.9) | y |  |
| Nevrkla 1974 4425623 | 200 | BCC | D2. Brachytherapy/Pleisiotherapy | implant of radium needles or radon seeds | Recurrence | 3/36 (8.3) |  | A vs. D2: 0.32 (0.03, 3.27) | y |  |
| Werlinger 2002 12472494 | 191 | SCC | A. Surgical Excision without interoperative evaluation |  | Recurrence |  | 0/20 (0) |  | n |  |
| Werlinger 2002 12472494 | 191 | SCC | C3. Curettage + diathermy | Curettage & Desiccation | Recurrence |  | 2/56 (3.6) |  | n |  |
| Werlinger 2002 12472494 | 191 | BCC | A. Surgical Excision without interoperative evaluation |  | Recurrence |  | 1/90 (1.1) | A vs. C3: 0.37 (0.04, 3.63) | n |  |
| Werlinger 2002 12472494 | 191 | BCC | C3. Curettage + diathermy | Curettage & Desiccation | Recurrence |  | 3/102 (2.9) |  | n |  |
| McIntosh 1983 6647186 | 186 | BCC | A. Surgical Excision without interoperative evaluation |  | Recurrence |  | 5/62 (8.1) | A vs. D1: 4.25 (0.8, 22.65) | n |  |
| McIntosh 1983 6647186 | 186 | BCC | D1. External beam radiation |  | Recurrence |  | 2/99 (2) | D1 vs. C1: 0.33 (0.04, 2.44) | n |  |
| McIntosh 1983 6647186 | 186 | BCC | C1. Cryotherapy |  | Recurrence |  | 2/34 (5.9) | A vs. C1: 1.4 (0.26, 7.65) | n |  |
| Harrison 1987 3676083 | 123 | BCC | A. Surgical Excision without interoperative evaluation |  | Recurrence | 2/15 (13.3) |  | A vs. C3: 1.85 (0.15, 23.07) | y |  |
| Harrison 1987 3676083 | 123 | BCC | C3. Curettage + diathermy | Curettage and cautery | Recurrence | 1/13 (7.7) |  |  | y |  |
| Mebed 2010 21503006 | 120 | BCC+SCC | A. Surgical Excision without interoperative evaluation | with and without adjuvant radiotherapy | Recurrence | 2/103 (1.9) |  |  | y |  |
| Mebed 2010 21503006 | 120 | BCC+SCC | F3. Topical or intralesional Interferon (INF)...Define:  | intralesional | Recurrence | 3/7 (42.9) |  |  | y |  |
| Mebed 2010 21503006 | 120 | BCC+SCC | D1. External beam radiation |  | Recurrence | 0/8 (0) |  |  | y |  |
| Tarstedt 2016 26841041 | 116 | Bowen's | E1. PDT: MAL + red light...Define:  |  | Lack of clinical clearance |  | 4/18 (22.2) | E1 vs. E2: 2.29 (0.22, 24.14) | n |  |
| Tarstedt 2016 26841041 | 116 | Bowen's | E2. PDT: ALA + blue light...Define:  |  | Lack of clinical clearance |  | 1/9 (11.1) |  | n |  |
| Tarstedt 2016 26841041 | 116 | nodal BCC | E1. PDT: MAL + red light...Define:  |  | Lack of clinical clearance |  | 4/25 (16) | E1 vs. E2: 1.02 (0.2, 5.2) | n |  |
| Tarstedt 2016 26841041 | 116 | nodal BCC | E2. PDT: ALA + blue light...Define:  |  | Lack of clinical clearance |  | 3/19 (15.8) |  | n |  |
| Tarstedt 2016 26841041 | 116 | superficial BCC | E1. PDT: MAL + red light...Define:  |  | Lack of clinical clearance |  | 5/39 (12.8) | E1 vs. E2: 1.08 (0.23, 4.97) | n |  |
| Tarstedt 2016 26841041 | 116 | superficial BCC | E2. PDT: ALA + blue light...Define:  |  | Lack of clinical clearance |  | 3/25 (12) |  | n |  |
| Avila 1977 589557 | 97 | BCC+SCC (pinna) | A. Surgical Excision without interoperative evaluation |  | Recurrence | 2/50 (4) |  | A vs. D1: 0.27 (0.05, 1.42) | y |  |
| Avila 1977 589557 | 97 | BCC+SCC (pinna) | D1. External beam radiation | x-rays | Recurrence | 6/45 (13.3) |  |  | y |  |
| Wang 2016 | 95 | BCC | E3. PDT other (specify)...Define:  | PDT combined with the application of the topical photosensitizer ALA and systemic light-sensitive drug HPD | Lack of clinical clearance | 0/9 (0) | 0/14 (0) |  | n |  |
| Wang 2016 | 95 | BCC | E3. PDT other (specify)...Define:  | HPD-PDT | Lack of clinical clearance | 2/13 (15.4) | 2/13 (15.4) |  | n |  |
| Wang 2016 | 95 | BCC | E2. PDT: ALA + blue light...Define:  | ALA‑PDT following CO2 laser vaporization | Lack of clinical clearance | 0/14 (0) | 0/14 (0) |  | n |  |
| Wang 2016 | 95 | SCC | E3. PDT other (specify)...Define:  | PDT combined with the application of the topical photosensitizer ALA and systemic light-sensitive drug HPD | Lack of clinical clearance |  | 1/26 (3.8) |  | n |  |
| Wang 2016 | 95 | SCC | E3. PDT other (specify)...Define:  | HPD-PDT | Lack of clinical clearance | 0/10 (0) | 0/10 (0) |  | n |  |
| Wang 2016 | 95 | SCC | E2. PDT: ALA + blue light...Define:  | ALA‑PDT following CO2 laser vaporization | Lack of clinical clearance |  | 2/18 (11.1) |  | n |  |
| Cox 1995 7669642 | 91 | Bowen's | C1. Cryotherapy |  | Recurrence |  | 6/82 (7.3) |  | y |  |
| Cox 1995 7669642 | 91 | Bowen's | D1. External beam radiation |  | Recurrence |  | 0/59 (0) |  | y |  |
| Kowalzick 1994 | 87 | BCC | F3. Topical or intralesional Interferon (INF)...Define:  | intralesional 1 MU/weekly for 3 weeks | Lack of clinical clearance | 4/7 (57.1) |  |  | y |  |
| Kowalzick 1994 | 87 | BCC | F3. Topical or intralesional Interferon (INF)...Define:  | intralesional 3 MU/weekly for 3 weeks | Lack of clinical clearance | 6/7 (85.7) |  |  | y |  |
| Kowalzick 1994 | 87 | BCC | F3. Topical or intralesional Interferon (INF)...Define:  | intralesional 0.5 MU/twice weekly for 3 weeks | Lack of clinical clearance | 6/7 (85.7) |  |  | y |  |
| Kowalzick 1994 | 87 | BCC | F3. Topical or intralesional Interferon (INF)...Define:  | intralesional 1 MU/twice weekly for 3 weeks | Lack of clinical clearance | 6/10 (60) |  |  | y |  |
| Kowalzick 1994 | 87 | BCC | F3. Topical or intralesional Interferon (INF)...Define:  | intralesional 3 MU/twice weekly for 3 weeks | Lack of clinical clearance | 5/10 (50) |  |  | y |  |
| Kowalzick 1994 | 87 | BCC | F3. Topical or intralesional Interferon (INF)...Define:  | intralesional 0.5 MU/three times weekly for 3 weeks | Lack of clinical clearance | 5/14 (35.7) |  |  | y |  |
| Kowalzick 1994 | 87 | BCC | F3. Topical or intralesional Interferon (INF)...Define:  | intralesional 1 MU/three times weekly for 3 weeks | Lack of clinical clearance | 2/14 (14.3) |  |  | y |  |
| Reschly 2010 20677531 | 75 | SCC (males over age 60) | C3. Curettage + diathermy | Curettage & Electrodesiccation | Recurrence |  | 0/14 (0) |  | n |  |
| Reschly 2010 20677531 | 75 | SCC (males over age 60) | A. Surgical Excision without interoperative evaluation |  | Recurrence |  | 1/16 (6) |  | n |  |
| Bean 1984 6463702 | 70 | BCC+SCC (hand) | A. Surgical Excision without interoperative evaluation |  | Recurrence |  | 2/67 (3) |  | n | metastasis |
| Bean 1984 6463702 | 70 | BCC+SCC (hand) | D1. External beam radiation |  | Recurrence |  | 1/3 (33.3) |  | n | metastasis |
| Bean 1984 6463702 | 70 | BCC+SCC (hand) | F1. Topical or intralesional 5-FU...Define:  |  | Recurrence |  | 3/3 (100) |  | n | metastasis |
| Bean 1984 6463702 | 70 | BCC+SCC (hand) | C2. Diathermy/electrodessication |  | Recurrence |  | 1/3 (33.3) |  | n | metastasis |
| Bean 1984 6463702 | 70 | BCC+SCC (hand) | C1. Cryotherapy |  | Recurrence |  | 1/3 (33.3) |  | n | metastasis |
| Cham 1991 1913614 | 41 | BCC | F5. Medical other...Define:  | BEC (Curaderm) | Lack of clinical clearance |  | 0/39 (0) |  | y |  |
| Cham 1991 1913614 | 41 | BCC | F5. Medical other...Define:  | placebo | Lack of clinical clearance |  | 2/2 (100) |  | y |  |
| Aguilar 2010 20456549 | 67 | BCC+SCC | A. Surgical Excision without interoperative evaluation |  | Lack of clinical clearance (1-efficacy) |  | 1/34 (2.5) | A vs. E1: 0.25 (0.02, 2.58) | n | costs |
| Aguilar 2010 20456549 | 67 | BCC+SCC | E1. PDT: MAL + red light...Define:  |  | Lack of clinical clearance (1-efficacy) |  | 3/28 (10.5) | E1 vs. F2: 0.84 (0.15, 4.61) | n | costs |
| Aguilar 2010 20456549 | 67 | BCC+SCC | F2. Topical or intralesional Imiquimod...Define:  | topical | Lack of clinical clearance (1-efficacy) |  | 3/24 (12.5) | A vs. F2: 0.21 (0.02, 2.18) | n | costs |
| Marks 2004 | 67 | BCC | F2. Topical or intralesional Imiquimod...Define:  | topical 5 times/week | Lack of clinical clearance | 0/36 (0) |  |  | y |  |
| Marks 2004 | 67 | BCC | F2. Topical or intralesional Imiquimod...Define:  | topical 7 times/week | Lack of clinical clearance | 2/30 (7) |  |  | y |  |
| Kadakia 2016 26780196 | 53 | SCC (scalp) immunocompromised | A. Surgical Excision without interoperative evaluation | Surgical excision or Mohs with post-operative radiation | Recurrence | 8/45 (17.8) |  | A + D1 vs A: 0.36 (0.07, 1.83) | y | metastasis/death |
| Kadakia 2016 26780196 | 53 | SCC (scalp) immunocompromised | A. Surgical Excision without interoperative evaluation | Surgical excision or Mohs | Recurrence | 3/8 (37.5) |  |  | y | metastasis/death |
| Shiffman 1975 1125865 | 52 | SCC (pinna) | A. Surgical Excision without interoperative evaluation |  | Recurrence | 2/31 (6.5) |  | A vs. C3: 0.19 (0.03, 1.19) | n | metastasis |
| Shiffman 1975 1125865 | 52 | SCC (pinna) | C3. Curettage + diathermy | curettage + electrodessication or surgery | Recurrence | 4/15 (26.7) |  |  | n | metastasis |
| Ibbotson 2012 22971196 | 40 | BCC | E1. PDT: MAL + red light...Define:  |  | Lack of clinical clearance | 8/20 (40) |  | E1 vs. E2: 1.24 (0.34, 4.46) | y |  |
| Ibbotson 2012 22971196 | 40 | BCC | E2. PDT: ALA + blue light...Define:  |  | Lack of clinical clearance | 7/20 (35) |  |  | y |  |
| Yoon 1992 1463102 | 40 | SCC | A. Surgical Excision without interoperative evaluation | excision only | Recurrence | 8/13 (62) |  | A vs. B: 3.52 (0.76, 16.39) | n | metastasis/death |
| Yoon 1992 1463102 | 40 | SCC | B. Surgical Excision with interoperative evaluation | Mohs | Recurrence | 5/16 (31) |  |  | n | metastasis/death |
| Glass 1974 4808574 | 24 | epidermoid carcinoma; incompletely excised | A. Surgical Excision without interoperative evaluation |  | Recurrence | 2/19 (10.5) |  | A vs. D1: 0.47 (0.03, 6.57) | n |  |
| Glass 1974 4808574 | 24 | epidermoid carcinoma; incompletely excised | D1. External beam radiation | radiotherapy | Recurrence | 1/5 (20) |  |  | n |  |
| Valentine 2011 21077899 | 40 | BCC | E1. PDT: MAL + red light...Define:  | 10 gp2 |  |  |  |  | y |  |
| Valentine 2011 21077899 | 40 | BCC | E2. PDT: ALA + blue light...Define:  | 10 gp1 |  |  |  |  | y |  |
| Valentine 2011 21077899 | 40 | Bowen's | E1. PDT: MAL + red light...Define:  | 10 gp 4 |  |  |  |  | y |  |
| Valentine 2011 21077899 | 40 | Bowen's | E2. PDT: ALA + blue light...Define:  | 10 gp 3 |  |  |  |  | y |  |
| Halnan 1968 5710508 | 104 | BCC + SCC | A. Surgical Excision without interoperative evaluation | 10 lesions |  |  |  |  | y | cosmetic outcomes |
| Halnan 1968 5710508 | 104 | BCC + SCC | D1. External beam radiation | x-ray therapy = 58 lesions |  |  |  |  | y | cosmetic outcomes |
| Halnan 1968 5710508 | 104 | BCC + SCC | D2. Brachytherapy/Pleisiotherapy | radon gold see implant = 38 lesions |  |  |  |  | y | cosmetic outcomes |
| Bu 2016 27888160 | 20 | BCC | E2. PDT: ALA + blue light...Define:  | Excision + ALA PDT | Recurrence | 0/10 (0) |  |  |  |  |
| Bu 2016 27888160 | 20 | BCC | A. Surgical Excision without interoperative evaluation | Excision + excision | recurrence | 0/10 (0) |  |  |  |  |
| Haseltine 2016 27504127 | 61 | BCC + SCC | D2. Brachytherapy/Pleisiotherapy |  | Lack of clinical clearance | 0/8 (0) |  | D2 vs D1: 0.04 (0, 21.14) | y | cosmetic outcomes |
| Haseltine 2016 27504127 | 61 | BCC + SCC | D1. External beam radiation | hypofractionation | Lack of clinical clearance | 7/29 (24) |  | D2 vs D1: 0.05 (0, 27.38) | y | cosmetic outcomes |
| Haseltine 2016 27504127 | 61 | BCC + SCC | D1. External beam radiation | standard fractionation | Lack of clinical clearance | 4/20 (20) |  | D1 vs D1:1.27 (0.32, 5.09) | y | cosmetic outcomes |
| Salido-Vallejo 2016 26369617 | 86 | SCC (infiltrating) | F5. Medical other...Define:  | Methotrexate + excision | tumor area reduction | 43 | neg 0.52 cm2 (0.85) | mean difference -1.01 (-1.38, -0.64) P<0.001 | y |  |
| Salido-Vallejo 2016 26369617 | 86 | SCC (infiltrating) | A. Surgical Excision without interoperative evaluation | excision only | tumor area reduction | 43 | 0.49 cm2 (0..88) |  | y |  |
| Overmark 2016 26073523 | 239 | SCC (in situ) | A. Surgical Excision without interoperative evaluation |  | recurrence |  | 1/125 (0.8) | A vs. C1: 0.16 (0.02, 1.61) |  |  |
| Overmark 2016 26073523 | 239 | SCC (in situ) | C1. Cryotherapy |  | recurrence |  | 3/64 (4.7) | C1 vs E1: 0.23 (0.06, 0.85) |  |  |
| Overmark 2016 26073523 | 239 | SCC (in situ) | E1. PDT: MAL + red light...Define:  |  | recurrence |  | 13/74 (18) | A vs E1: 0.04 (0, 0.3) |  |  |
| Nassiripour\_2016\_28163737 | 630 | BCC + SCC | A. Surgical Excision without interoperative evaluation |  | recurrence | 28/354 (7.9)  |  | A vs B: 0.9 (0.51, 1.59) |  |  |
| Nassiripour\_2016\_28163737 | 630 | BCC + SCC | B. Surgical Excision with interoperative evaluation |  | recurrence | 24/276 (8.7) |  |  |  |  |
| Marconi 2016 | 597 | BCC + SCC | D1. External beam radiation | 2 Gy | lack of histological clearance |  | 32/500 (6.4) | D1 (high dose) vs. D1 (low dose): 0.26 (0.12, 0.54) | y |  |
| Marconi 2016 | 597 | BCC + SCC | D1. External beam radiation | > 2 Gy | lack of histological clearance |  | 9/521 (1.7) |  | y |  |